Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 147

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 147
---
 Warrants, if such Depositary Shares, Pre-Funded Warrants,
or Series L Warrants are not held on such holder’s behalf by a financial institution, as our ordinary shares are considered “specified
foreign financial assets.” This law also imposes penalties and potential other adverse tax consequences if a U.S. Holder is required
to submit such information to the IRS and fails to do so. U.S. Holders are urged to consult their tax advisors regarding the potential
information reporting obligations that may be imposed with respect to the ownership and disposition of the Depositary Shares, Pre-Funded Warrants,
or Series L Warrants.

THE DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL TAX MATTERS THAT MAY BE OF IMPORTANCE TO A PARTICULAR INVESTOR. EACH PROSPECTIVE INVESTOR IN OUR SECURITIES IS URGED TO CONSULT ITS OWN TAX ADVISER ABOUT THE TAX CONSEQUENCES TO IT OF OWNING AND DISPOSING OF OUR SECURITIES IN LIGHT OF SUCH PROSPECTIVE INVESTOR’S OWN CIRCUMSTANCES.

| 85 |

<div align='center'>PLAN OF DISTRIBUTION</div>

We are offering on a reasonable best efforts
basis up to 3,377,110 Units, consisting of one Depositary Share (representing Ordinary Shares) and one Series L Warrant, or up to 3,377,110
Pre-Funded Units, consisting of one Pre-Funded Warrant and one Series L Warrant, at a combined public offering price of $5.33 per Unit
(or, in the case of Pre-Funded Units, $5.3299), which represents the closing price of our Depositary Shares on the NASDAQ Capital Market
on November 12, 2025, for gross proceeds of up to $18.0 million, before deduction of placement agent commissions and offering expenses,
in a best-efforts offering. There is no minimum amount of proceeds that is a condition to closing of this offering. The actual amount
of gross proceeds, if any, in this offering could vary substantially from the gross proceeds from the sale of the maximum number of securities
being offered in this prospectus.

Pursuant to a placement agency
agreement, dated as of , 2025, we have engaged Maxim Group LLC to act as
our exclusive placement agent to solicit offers to purchase the securities offered by this prospectus. The placement agent is not purchasing
or selling any securities, nor is it required to